1
|
Neumann R, Thomann R, Goerres GW. A retrospective study with long term follow-up of Graves' disease patients treated with low activities of 131Iodine. THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING : OFFICIAL PUBLICATION OF THE ITALIAN ASSOCIATION OF NUCLEAR MEDICINE (AIMN) [AND] THE INTERNATIONAL ASSOCIATION OF RADIOPHARMACOLOGY (IAR), [AND] SECTION OF THE SOCIETY OF... 2024; 68:116-125. [PMID: 36287041 DOI: 10.23736/s1824-4785.22.03468-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
BACKGROUND Previous studies have shown that application of relatively low 131I-Iodine activities can successfully be used to treat patients with Graves' disease (GD). We assessed treatment outcome in the long-term follow-up of our GD patients and influencing factors. METHODS We evaluated 521 GD patients in this retrospective clinical single-center study. In all patients we performed scintigraphy and thyroid uptake measurement after 4 and 24 hours using 10 MBq 123I and calculated administered activity using Marinellis' formula. Treatment was done according to national regulations. Minimal routine clinical evaluation of all patients was available after 6 weeks and after 3, 6 and 12 months. Success of treatment was defined as euthyroid state or hypothyroidism 6 months after therapy. RESULTS We usually applied relatively low 131I activities. Three hundred seven patients (58.9%) became hypothyroid within 21 years of follow-up. One hundred thirty-nine patients (26.7%) became euthyroid and stayed euthyroid until the end of follow-up. We found a plateau after 7 years of initial therapy with only a few patients becoming hypothyroid after that time and identified 75 patients (14.4%) with persistent hyperthyroidism or recurrence. CONCLUSIONS Treatment with relatively low 131I activities produce favorable responses as shown in previous works. We found a high proportion of patients with long-term euthyroid state. Application of low activities reduces radiation burden of patients and, depending on radiation protection legislation, may lead to shortened hospital stay and reduced costs. Therefore, we feel that application of higher activities to treat GD patients as recommended in several current guidelines should be reconsidered.
Collapse
Affiliation(s)
- Regina Neumann
- Department of Radiology and Nuclear Medicine, GZO Spital Wetzikon, Wetzikon, Switzerland
| | - Robert Thomann
- Center for Metabolic Disease, Buergerspital Solothurn, Solothurn, Switzerland
| | | |
Collapse
|
2
|
Traino CA. Dosimetry of 131I treatment in benign thyroid diseases. Nucl Med Mol Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00200-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
3
|
Taprogge J, Gape PM, Carnegie-Peake L, Murray I, Gear JI, Leek F, Hyer SL, Flux GD. A Systematic Review and Meta-Analysis of the Relationship Between the Radiation Absorbed Dose to the Thyroid and Response in Patients Treated with Radioiodine for Graves' Disease. Thyroid 2021; 31:1829-1838. [PMID: 34598656 PMCID: PMC8721505 DOI: 10.1089/thy.2021.0302] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Background: Patients with Graves' disease are commonly treated with radioiodine. There remains controversy over whether the aim of treatment should be to achieve euthyroidism or hypothyroidism, and whether treatments should be administered with standard levels of radioactivity or personalized according to the radiation absorbed doses delivered to the thyroid. The aim of this review was to investigate whether a relationship exists between radiation absorbed dose and treatment outcome. Methods: A systematic review and meta-analysis of all reports published before February 13, 2020, were performed using PubMed, Web of Science, OVID MEDLINE, and Embase. Proportion of patients achieving nonhyperthyroid status was the primary outcome. Secondary outcomes were proportion of patients who were specifically euthyroid or hypothyroid. A random-effects meta-analysis of proportions was performed for primary and secondary outcomes, and the impact of the radiation absorbed dose on treatment outcome was assessed through meta-regression. The study is registered with PROSPERO (CRD42020175010). Results: A total of 1122 studies were identified of which 15, comprising 2303 Graves' disease patients, were eligible for the meta-analysis. A strong association was found between radiation absorbed dose and nonhyperthyroid and hypothyroid outcomes (odds ratio [OR] = 1.11 [95% confidence interval {CI} 1.08-1.14] and OR = 1.09 [CI 1.06-1.12] per 10 Gy increase). Higher rates of euthyroid outcome were found for radiation absorbed doses within the range 120-180 Gy when compared with outside this range (n = 1172, OR = 2.50 [CI 1.17-5.35], p = 0.018). A maximum euthyroid response of 38% was identified at a radiation absorbed dose of 128 Gy. Conclusions: The presented radiation absorbed dose-response relationships can facilitate personalized treatment planning for radioiodine treatment of patients with Graves' disease. Further studies are required to determine how patient-specific covariates can inform personalized treatments.
Collapse
Affiliation(s)
- Jan Taprogge
- Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom
- The Institute of Cancer Research, London, United Kingdom
- Address correspondence to: Jan Taprogge, PhD, Joint Department of Physics, Royal Marsden NHSFT, Downs Road, Sutton SM2 5PT, United Kingdom
| | - Paul M.D. Gape
- Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom
- The Institute of Cancer Research, London, United Kingdom
| | - Lily Carnegie-Peake
- Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom
- The Institute of Cancer Research, London, United Kingdom
| | - Iain Murray
- Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom
- The Institute of Cancer Research, London, United Kingdom
| | - Jonathan I. Gear
- Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom
- The Institute of Cancer Research, London, United Kingdom
| | - Francesca Leek
- Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom
- The Institute of Cancer Research, London, United Kingdom
| | - Steve L. Hyer
- Department of Endocrinology, Epsom and St Helier University Hospitals NHS Trust, Carshalton, Surrey, United Kingdom
| | - Glenn D. Flux
- Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom
- The Institute of Cancer Research, London, United Kingdom
| |
Collapse
|
4
|
Al‐Shakhrah IA. An indirect high iodine ( 131 I) effective dose used for thyroid ablation in patients with thyroid cancer. Is the method of measurement important? J Appl Clin Med Phys 2020; 21:173-180. [PMID: 32573916 PMCID: PMC7386177 DOI: 10.1002/acm2.12901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2019] [Revised: 03/15/2020] [Accepted: 03/19/2020] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND Radiation effective dose to the red bone-marrow, a critical organ in the therapy of differentiated thyroid carcinoma (DTC) with radioiodine-131 (131 I), cannot be measured directly. As radioiodine concentration is comparable in blood and most organs, and is believed to be similar in red marrow, the effective dose to the blood seems to be a good first-order approximation of the radiation effective dose to the hematopoietic system and a better means to quantifying exposure from therapy compared to the total amount of activity administered. PURPOSE We applied four formulas (Lassmann et al (standard) [2008], Eur J Nucl Med Molecul Imaging, 35:1405-1412), (Thomas et al. [1993], Nucl Med Biol, 20:157-162), (Sisson et al. [2003], J Nucl Med, 44:898-903; Ha¨nscheid et al. [2009], Endocr Relat Cancer, 16:1283-1289) and (Ha¨nscheid et al. [2006], J Nucl Med, 47:648-654) and compared between the estimated values of the effective dose that were obtained by three formulas and those obtained by the standard one. MATERIALS AND METHODS Twenty-seven patients, 22 women and 5 men, suffering from DTC were enrolled in this study. Whole-body probe measurements and blood collections (2 mL whole-blood samples) were conducted at 2, 6, 24, 48, 72-96 h after the administration of 131 I to obtain time-activity curves. Whole-body measurements were performed as conjugate view (anterior and posterior) counts by scintillation camera imaging. RESULTS By comparing the values of blood effective dose that were obtained by applying Thomas et al. [1993], Nucl Med Biol, 20:157-162; Sisson et al. [2003], J Nucl Med, 44:898-903 and Ha¨nscheid et al. [2009], Endocr Relat Cancer, 16:1283-1289, and Ha¨nscheid et al. [2006], J Nucl Med, 47:648-654, techniques, with those obtained by (Lassmann et al (standard technique) [2008], Eur J Nucl Med Molecul Imaging, 35:1405-1412), we found that these values are, respectively, 15.0%, 40.0%, and 41.0% more than those obtained by using the standard method. To our knowledge no papers have been published previously that compare between these dosimetric approaches. CONCLUSION Highly overestimated or highly underestimated results obtained by a certain method or technique, compared with those obtained by the standard method, are not desirable, they tend to exaggerate in applying radiation protection procedures, by increasing or decreasing, which, in both cases, become far from the realistic or recommended procedures. As an operating philosophy, the objective of radiation safety practices simply should not be to keep radiation doses within legal limits or maximum permissible doses (MPDs ), but to keep them "as low as reasonably achievable" (ALARA concept). MPDs should not be considered as thresholds below which exposure to radiation is of no concern, they are not assumed to be totally risk free, and any reasonable technique for reducing radiation dose may have potential benefits in the long run.
Collapse
|
5
|
Jaiswal AK, Bal C, Damle NA, Ballal S, Goswami R, Hari S, Kumar P. Comparison of clinical outcome after a fixed dose versus dosimetry-based radioiodine treatment of Graves' disease: Results of a randomized controlled trial in Indian population. Indian J Endocrinol Metab 2014; 18:648-654. [PMID: 25285281 PMCID: PMC4171887 DOI: 10.4103/2230-8210.139222] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
OBJECTIVE Two approaches are used to treat Graves' disease with radioiodine ((131)I)-the fixed dose approach and the other based on dosimetry. A prospective study was performed to compare the results of these two approaches in a randomized patient population, as such study is lacking in the Indian population till date. MATERIALS AND METHODS Patients with Graves' disease were randomized into two groups: (1) Fixed dose group and the (2) Calculated dose group, each comprising of 20 patients. All the patients underwent detailed clinical and biochemical evaluation. Thyroid mass was determined by high resolution ultrasound machine with linear transducer of 7-11 MHz. Patients were given 185-370 kBq (5-10 uCi) of (131)I and 24 hr radioiodine uptake (RAIU) was calculated using thyroid uptake probe and thyroid phantom. Fixed dose group patients were administered 185MBq of (131)I. Calculated dose group patients were given (131)I as per the following formula: Calculated dose = [3700 kBq/g × estimated thyroid wt. (g)] ÷ 24 hr RAIU (%). Success of first dose of radioiodine was defined as clinically/biochemically euthyroid/hypothyroid status at the end of 3 months without the need for further therapy. RESULTS In the fixed dose group, eight patients were hyperthyroid, four were euthyroid, and eight were hypothyroid after the first dose at 3 months. Success rate of first dose was 60%. In calculated dose group, seven patients were hyperthyroid, eight were euthyroid, and five were hypothyroid. Success rate of first dose was 65%. CONCLUSIONS There is no statistically significant difference between the success rates of the two methods at 3 months. Hence, fixed dose approach may be used for treatment of Graves' disease as it is simple and convenient for the patient. Longer follow-up with higher number of patients should be done to confirm or contradict our findings.
Collapse
Affiliation(s)
- Abhishek Kumar Jaiswal
- Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
| | - Chandrasekhar Bal
- Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
| | | | - Sanjana Ballal
- Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
| | - Ravinder Goswami
- Department of Endocrinology, All India Institute of Medical Sciences, New Delhi, India
| | - Smriti Hari
- Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi, India
| | - Praveen Kumar
- Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
| |
Collapse
|
6
|
Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev 2012; 33:920-80. [PMID: 22961916 DOI: 10.1210/er.2012-1030] [Citation(s) in RCA: 160] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Radioiodine ((131)I) therapy of benign thyroid diseases was introduced 70 yr ago, and the patients treated since then are probably numbered in the millions. Fifty to 90% of hyperthyroid patients are cured within 1 yr after (131)I therapy. With longer follow-up, permanent hypothyroidism seems inevitable in Graves' disease, whereas this risk is much lower when treating toxic nodular goiter. The side effect causing most concern is the potential induction of ophthalmopathy in predisposed individuals. The response to (131)I therapy is to some extent related to the radiation dose. However, calculation of an exact thyroid dose is error-prone due to imprecise measurement of the (131)I biokinetics, and the importance of internal dosimetric factors, such as the thyroid follicle size, is probably underestimated. Besides these obstacles, several potential confounders interfere with the efficacy of (131)I therapy, and they may even interact mutually and counteract each other. Numerous studies have evaluated the effect of (131)I therapy, but results have been conflicting due to differences in design, sample size, patient selection, and dose calculation. It seems clear that no single factor reliably predicts the outcome from (131)I therapy. The individual radiosensitivity, still poorly defined and impossible to quantify, may be a major determinant of the outcome from (131)I therapy. Above all, the impact of (131)I therapy relies on the iodine-concentrating ability of the thyroid gland. The thyroid (131)I uptake (or retention) can be stimulated in several ways, including dietary iodine restriction and use of lithium. In particular, recombinant human thyrotropin has gained interest because this compound significantly amplifies the effect of (131)I therapy in patients with nontoxic nodular goiter.
Collapse
Affiliation(s)
- Steen Joop Bonnema
- Department of Endocrinology, Odense University Hospital, DK-5000 Odense C, Denmark.
| | | |
Collapse
|
7
|
Possibility of limiting the un-justified irradiation in 131I therapy of Graves' disease: A thyroid mass-reduction based method for the optimum activity calculation. Phys Med 2010; 26:71-9. [DOI: 10.1016/j.ejmp.2009.08.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/01/2009] [Revised: 06/28/2009] [Accepted: 08/29/2009] [Indexed: 11/19/2022] Open
|
8
|
Bozhok Y, Greenebaum E, Bogdanova TI, McConnell RJ, Zelinskaya A, Brenner AV, Zurnadzhy LY, Zablotska L, Tronko MD, Hatch M. NA cohort study of thyroid cancer and other thyroid diseases after the Chernobyl accident: cytohistopathologic correlation and accuracy of fine-needle aspiration biopsy in nodules detected during the first screening in Ukraine (1998-2000). Cancer 2009; 117:73-81. [PMID: 19365829 DOI: 10.1002/cncy.20002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND The Ukrainian American Cohort Study was established to evaluate the risk of thyroid disorders in a group exposed as children and adolescents to 131I by the Chernobyl accident (arithmetic mean thyroid dose, 0.79 grays). Individuals are screened by palpation and ultrasound and are referred to surgery according to fine-needle aspiration biopsy (FNA). However, the accuracy of FNA cytology for detecting histopathologically confirmed malignancy after this level of internal exposure to radioiodines is unknown. METHODS During the first screening cycle (1998-2000), 13,243 individuals were examined, 356 individuals with thyroid nodules were referred for FNA, 288 individuals completed the procedure, 85 individuals were referred to surgery, 82 individuals underwent surgery, and preoperative cytology was available for review in 78 individuals. Cytologic interpretation for the nodule that resulted in surgical referral was correlated with final pathomorphology; discrepancies were reviewed retrospectively; and the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of FNA cytology were calculated. RESULTS All 24 cytologic interpretations that were definite for papillary thyroid cancer (PTC) were confirmed histopathologically (PPV, 100%); and, of 11 cytologic interpretations that were suspicious for PTC, 10 were confirmed (PPV, 90.9%). Ten of 41 FNAs that were interpreted as either definite or suspect for follicular neoplasm were confirmed as malignant (PPV, 24.4%), including 2 follicular thyroid cancers and 8 PTCs (all but 1 of the follicular or mixed subtypes). Depending on whether a cytologic interpretation of follicular neoplasm was considered "positive" or "negative," the sensitivity was 100% and 77.3%, respectively; similarly, the respective specificity was 17.6% and 97.1%, the respective PPV was 61.1% and 97.1%, and the respective NPV was 100% and 76.7%. CONCLUSIONS Among children and adolescents who were exposed to 131I after the Chernobyl accident and were evaluated 12 to 14 years later, thyroid cytology had a sensitivity and a predictive value similar to those reported in unexposed populations.
Collapse
Affiliation(s)
- Yuriy Bozhok
- Institute of Endocrinology and Metabolism, Kiev, Ukraine
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Traino AC, Xhafa B. Accuracy of two simple methods for estimation of thyroidal I131 kinetics for dosimetry-based treatment of Graves’ disease. Med Phys 2009; 36:1212-8. [DOI: 10.1118/1.3093237] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
10
|
Strigari L, Sciuto R, Benassi M, Bergomi S, Nocentini S, Maini CL. A NTCP approach for estimating the outcome in radioiodine treatment of hyperthyroidism. Med Phys 2008; 35:3903-3910. [DOI: 10.1118/1.2964089] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
11
|
Markovic V, Eterovic D. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves' disease. J Clin Endocrinol Metab 2007; 92:3547-52. [PMID: 17609305 DOI: 10.1210/jc.2007-0879] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
CONTEXT Despite accounting for variations in gland size and iodine kinetics, the success of radioiodine therapy in patients with Graves' disease remains moderately common and unpredictable. OBJECTIVES We hypothesized that hypoechogenic glands, with large, densely packed cells, are more radiosensitive than normoechogenic glands, in which much radiation is wasted on more abundant colloid. We evaluated this hypothesis in a cohort of patients with Graves' disease. DESIGN This was a prospective trial of patients recruited during 4 yr and followed up 1 yr after radioiodine therapy. SETTING This trial was held in a university hospital-outpatient clinic. PATIENTS A total of 177 consecutive patients with first presentation of Graves' disease (28 males), 23-76 yr old, who relapsed after antithyroid therapy were included in the study. INTERVENTION The patients were assigned to an ablative target-absorbed dose of 200 Gy (n = 78) or randomly to 100 or 120 Gy of nonablative dose (n = 99). MAIN OUTCOME MEASURES The measures were incidences of hyperthyroidism, euthyroidism, and hypothyroidism at 12-month follow-up. RESULTS At follow-up there were 25 hyperthyroid, 44 euthyroid, and 108 hypothyroid patients. Compared with 96 patients with a hypoechogenic gland, in 81 patients with a normoechogenic gland, there were more hyperthyroid (22 vs. 7%) and euthyroid (41 vs. 11%), but less hypothyroid outcomes (37 vs. 81%; P < 0.0001). The other independent predictor of increased radioresistance was the large gland volume. CONCLUSION In patients with Graves' disease, normoechogenic and large glands are associated with increased radioresistance.
Collapse
Affiliation(s)
- Vinko Markovic
- Department of Nuclear Medicine, University Hospital Split, 21 000 Split, Croatia
| | | |
Collapse
|
12
|
Sisson JC, Avram AM, Rubello D, Gross MD. Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science? Eur J Nucl Med Mol Imaging 2007; 34:1129-30. [PMID: 17457585 DOI: 10.1007/s00259-007-0419-0] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2007] [Accepted: 02/26/2007] [Indexed: 10/23/2022]
|
13
|
Bozhok Y, Greenebaum E, Bogdanova TI, McConnell RJ, Zelinskaya A, Brenner AV, Zurnadzhy LY, Zablotska L, Tronko MD, Hatch M. A cohort study of thyroid cancer and other thyroid diseases after the Chornobyl accident: pathology analysis of thyroid cancer cases in Ukraine detected during the first screening (1998-2000). Cancer 2006; 107:2559-66. [PMID: 17083123 PMCID: PMC2983485 DOI: 10.1002/cncr.22321] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND The Ukrainian American Cohort Study evaluated the risk of thyroid disorders in a group of individuals who were younger than age 18 years at the time of the Chornobyl (Chernobyl) accident. In this article, the authors describe the pathology of thyroid carcinomas detected in the first screening. METHODS From 1998 to 2000, 13,243 individuals completed the first cycle of screening examinations. Eighty patients underwent surgery between 1998 and 2004. Intraoperative and postoperative pathologic studies were performed at the Institute of Endocrinology and Metabolism, Kyiv. RESULTS Pathologic analysis revealed 45 thyroid carcinomas, including 43 papillary thyroid carcinomas (PTCs) (95.6%) and 2 follicular thyroid carcinomas (FTCs) (4.4%). TNM classification (5th edition) of the PTCs included 8 T1 tumors (18.6%), 16 T2 tumors (37.2%), and 19 T4 tumors (44.2%). Fifteen PTCs (34.9%) were N1a,N1b, and 3 PTCs (7.0%) were M1. Among the PTCs, 8 exhibited the classical papillary histologic pattern (18.6%), 14 exhibited a follicular histologic pattern (32.6%), 5 exhibited a solid histologic pattern (11.6%), and 16 exhibited a mixed histologic pattern (37.2%). Both FTCs had a microfollicular-solid structure. Eleven of 20 cohort members who underwent surgery before the first screening had PTCs. Regional metastases (63.6%) and distant metastases (18.2%) were more common in this group. CONCLUSIONS Multifocal growth, lymphatic and blood vessel invasion, extrathyroid spread, and regional and distant metastases were more frequent in less differentiated PTCs (>30% solid structure). Small carcinomas (</=10 mm) comprised 23.3% of PTCs, and most of those (8 of 10 small carcinomas; 80%) were of the papillary-follicular subtype and therefore were more differentiated. The solid subtype of PTC was associated with shorter latency, especially in individuals who were diagnosed before the first screening. The histology of post-Chornobyl cancers is changing with time.
Collapse
Affiliation(s)
- Yuriy Bozhok
- Institute of Endocrinology and Metabolism, Kyiv, Ukraine
| | - Ellen Greenebaum
- College of Physicians and Surgeons, Columbia University, New York, NY, USA
| | | | | | | | | | | | - Lydia Zablotska
- Mailman School of Public Health, Columbia University, New York, NY USA
| | | | | |
Collapse
|
14
|
Traino AC, Di Martino F, Grosso M, Monzani F, Dardano A, Caraccio N, Mariani G, Lazzeri M. A study of the possibility of curing Graves?? disease based on the desired reduction of thyroid mass (volume) as a consequence of 131I therapy: a speculative paper. Nucl Med Commun 2006; 27:439-46. [PMID: 16609355 DOI: 10.1097/00006231-200605000-00005] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE The possibility of predicting the final volume of Graves' disease thyroids submitted to 131I therapy could allow the physician to decide what activity to administer based on the desired volume reduction instead of on a fixed value of the thyroid radiation absorbed dose. In this paper the relationship between maximum uptake of 131I, fractional reduction of thyroid volume and outcome of Graves' disease is discussed. METHODS The results are based on ultrasonography thyroid volume measurements before administration of therapy and at the moment of recovery from Graves' disease (thyroid stimulating hormone >0.3 microIU x ml(-1) in the absence of anti-thyroid drug therapy) and on measurements of 131I uptake in 40 patients. It is shown that the possibility of curing Graves' disease may be individually related to the final volume of the patient's thyroid. An equation is presented to calculate the 'optimal' final thyroid volume. RESULTS A comparison between the traditional method, based on absorbed dose, and the final method, based on volume, has been carried out retrospectively. In the first case a median activity of 529 MBq has been administered; in the second, a median activity of 394 MBq (non-parametric Wilcoxon test, P<0.05) should be administered. The corresponding thyroid median absorbed doses are, respectively, 353 Gy and 320 Gy (non-parametric Wilcoxon test, P<0.02). CONCLUSION A method to evaluate individually the 'optimal' final thyroid mass is presented and discussed. The method based on 'volume reduction' could probably reduce the activity and the thyroid absorbed dose compared to the method based on 'empirical' calculations, thus allowing the administration of 131I therapy to be optimized.
Collapse
Affiliation(s)
- Antonio C Traino
- Sezione di Fisica Medica, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Traino AC, Di Martino F, Grosso M, Monzani F, Dardano A, Caraccio N, Mariani G, Lazzeri M. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I. Phys Med Biol 2005; 50:2181-91. [PMID: 15843745 DOI: 10.1088/0031-9155/50/9/018] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Substantial reductions in thyroid volume (up to 70-80%) after radioiodine therapy of Graves' hyperthyroidism are common and have been reported in the literature. A relationship between thyroid volume reduction and outcome of 131I therapy of Graves' disease has been reported by some authors. This important result could be used to decide individually the optimal radioiodine activity A0 (MBq) to administer to the patient, but a predictive model relating the change in gland volume to A0 is required. Recently, a mathematical model of thyroid mass reduction during the clearance phase (30-35 days) after 131I administration to patients with Graves' disease has been published and used as the basis for prescribing the therapeutic thyroid absorbed dose. It is well known that the thyroid volume reduction goes on until 1 year after therapy. In this paper, a mathematical model to predict the final mass of Graves' diseased thyroids submitted to 131I therapy is presented. This model represents a tentative explanation of what occurs macroscopically after the end of the clearance phase of radioiodine in the gland (the so-called second-order effects). It is shown that the final thyroid mass depends on its basal mass, on the radiation dose absorbed by the gland and on a constant value alpha typical of thyroid tissue. Alpha has been evaluated based on a set of measurements made in 15 reference patients affected by Graves' disease and submitted to 131I therapy. A predictive equation for the calculation of the final mass of thyroid is presented. It is based on macroscopic parameters measurable after a diagnostic 131I capsule administration (0.37-1.85 MBq), before giving the therapy. The final mass calculated using this equation is compared to the final mass of thyroid measured 1 year after therapy administration in 22 Graves' diseased patients. The final masses calculated and measured 1 year after therapy are in fairly good agreement (R = 0.81). The possibility, for the physician, to decide a therapeutic activity based on the desired decrease of thyroid mass instead of on a fixed thyroid absorbed dose could be a new opportunity to cure Graves' disease.
Collapse
Affiliation(s)
- Antonio C Traino
- Sezione di Fisica Medica--U.O. Fisica Sanitaria, Azienda Ospedaliera Universitaria Pisana, via Roma 67, 56125 Pisa, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
Large goitres are common in the developing world, particularly in Asia and Africa. Nonetheless, large fungating goitres are extremely rare and represent a unique challenge to surgeons. Surgery should always be considered, when the general condition of the patient permits, to provide a better quality of life as it offers the only hope of long-term survival. The potential gain with surgery is that it allows maximum benefit for more effective radioactive iodine ablation and radiotherapy treatment. We report two cases of large fungating thyroid cancers complicated by anaemia and foul-smelling discharge.
Collapse
Affiliation(s)
- Kaur D Harjit
- Department of Breast and Endocrine Surgery, Putrajaya Hospital, Precinct 7, 62250 Putrajaya, Malaysia
| | | |
Collapse
|
17
|
Jönsson H, Mattsson S. Single uptake measurement for absorbed dose planning for radioiodine treatment of hyperthyroidism. Cancer Biother Radiopharm 2003; 18:473-9. [PMID: 12954135 DOI: 10.1089/108497803322285233] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
One or several radioiodine uptake measurements are usually made to calculate the activity necessary to give the prescribed absorbed dose to the thyroid of patients treated for hyperthyroidism. If the initial uptake, estimated at time zero, and the effective half-time are to be determined, more than one uptake measurement is needed. The first measurement is often made 24 h after administration of radioiodine. In this work we show that one uptake measurement taken at an appropriate time postadministration is sufficient to determine the product of the initial uptake and the effective half-time, and thus give an estimate of the absorbed dose. A total of 515 patients (14-92 years) who received radioiodine treatment for hyperthyroidism at Malmö University Hospital were analyzed. Individual effective half-times were determined from three uptake measurements, 24 h, 48 h, and a third measurement between 3 and 8 days after the intake of the test activity and were used for the absorbed dose calculations. We found a significant linear relationship between the uptake at 4 days or longer after administration and the product of initial uptake and effective half-time. The relationship was independent on diagnosis, age, and sex of the patient. Therefore a single uptake measurement is sufficient for an accurate absorbed dose determination, provided that the measurement is made at least 4 days after administration.
Collapse
Affiliation(s)
- Helene Jönsson
- Department of Radiation Physics, Malmö University Hospital, Malmö, Sweden.
| | | |
Collapse
|
18
|
Matheoud R, Canzi C, Reschini E, Zito F, Voltini F, Gerundini P. Tissue-specific dosimetry for radioiodine therapy of the autonomous thyroid nodule. Med Phys 2003; 30:791-8. [PMID: 12772986 DOI: 10.1118/1.1567270] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
A tissue-specific dosimetric method based on gamma camera acquisitions was developed to determine the 131I activity to administer to patients with autonomous thyroid nodules (ATN) to deliver 200 Gy to the nodule and to evaluate the correspondent dose to extranodular tissue. Twenty patients with ATN were given 111 MBq of 123I i.v. and their neck was imaged 2, 4, 24, 48, and 120 hours after administration to evaluate separate iodine kinetics for nodule and contralateral lobe. The volumes of nodule and lobe were measured on the 4 hour scintigraphic image, after optimization of the method on a thyroid phantom. Three simplified dosimetric methods were then considered and compared to the reference method in terms of 131I activity: (a) three point method, based on 4, 24, and 120 h acquisitions, (b) fixed T1/2 method, that measures only the 24 h uptake and assumes an effective half-life of 5 days for the nodule, (c) fixed activity method, based on the administration of 413 MBq of 131I. The mean 131I activity to administer to the 20 patients was 413 MBq (range 65-1327) and the mean dose to the contralateral lobe was 43 Gy (range 11-121). The percentage differences in 131I activity between the reference method and the simplified methods were in the ranges: (a) -14%, 13%, (b) -42%, 74%, (c) -69%, 533%. The relevant dose to extranodular tissue and the great interpatient variability of the radioiodine activity required to give a predetermined dose to ATN suggest that a tissue specific dosimetric approach based on gamma camera acquisitions is fundamental. A simple method based on only three uptake measurements is a reliable alternative to the five point method when the clinical workload of a Nuclear Medicine department is particularly heavy.
Collapse
Affiliation(s)
- Roberta Matheoud
- Department of Nuclear Medicine, Ospedale Maggiore di Milano, Milan, Italy.
| | | | | | | | | | | |
Collapse
|
19
|
Di Martino F, Traino AC, Brill AB, Stabin MG, Lazzer M. A theoretical model for prescription of the patient-specific therapeutic activity for radioiodine therapy of Graves' disease. Phys Med Biol 2002; 47:1493-9. [PMID: 12043815 DOI: 10.1088/0031-9155/47/9/305] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
A fundamental function of the thyroid is to extract iodine from the blood, synthesize it into thyroid hormones, and release it into the circulation under feedback control by pituitary-secreted hormones. This capability of the thyroid, termed as functionality, can in principle be related to the severity of hyperthyroidism in individual patients. In this paper the uptake and release of 131I by the thyroid following the administration of 131I therapy for Graves' disease has been theoretically studied. The kinetics of iodine in the thyroid and blood have been evaluated using a two-compartment model. This simplified model appears to be adequate for dosimetry purposes and allows one to correlate levels of increased thyroid functionality (hyperthyroidism) with clinically measurable kinetic parameters. An expression has been derived for the rate of change of thyroid mass following therapy; this has the same form as an empirical relationship described in an earlier work. A method is presented for calculation of the amount of radioiodine activity to be administered to individual patients in order to achieve the desired final functionality of the gland. The activity to be administered is based on measurements of 131I kinetics after the administration of a 'low-activity' (1850 kBq) tracer for treatment planning.
Collapse
Affiliation(s)
- F Di Martino
- Servizio di Fisica Sanitaria, Ospedale S Chiara, Pisa, Italy
| | | | | | | | | |
Collapse
|
20
|
Doi SAR, Loutfi I, Al-Shoumer KAS. A mathematical model of optimized radioiodine-131 therapy of Graves' hyperthyroidism. BMC NUCLEAR MEDICINE 2001; 1:1. [PMID: 11570980 PMCID: PMC56607 DOI: 10.1186/1471-2385-1-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/02/2001] [Accepted: 08/28/2001] [Indexed: 11/10/2022]
Abstract
BACKGROUND: The current status of radioiodine-131 (RaI) dosimetry for Graves' hyperthyroidism is not clear. Recurrent hyperthyroidism and iatrogenic hypothyroidism are two problems which interact such that trying to solve one leads to exacerbation of the other. Optimized RaI therapy has therefore begun to be defined just in terms of early hypothyroidism (ablative therapy) as physicians have given up on reducing hypothyroidism. METHODS: Optimized therapy is evaluated both in terms of the greatest separation of cure rate from hypothyroidism rate (non-ablative therapy) or in terms of early hypothyroidism (ablative therapy) by mathematical modeling of outcome after radioiodine and critically discussing the three common methods of RaI dosing for Graves' disease. RESULTS: Cure follows a logarithmic relationship to activity administered or absorbed dose, while hypothyroidism follows a linear relationship. The effect of including or omitting factors in the calculation of the administered I-131 activity such as the measured thyroid uptake and effective half-life of RaI or giving extra compensation for gland size is discussed. CONCLUSIONS: Very little benefit can be gained by employing complicated methods of RaI dose selection for non-ablative therapy since the standard activity model shows the best potential for cure and prolonged euthyroidism. For ablative therapy, a standard MBq/g dosing provides the best outcome in terms of cure and early hypothyroidism.
Collapse
Affiliation(s)
- Suhail AR Doi
- Endocrinology, Mubarak Al Kabeer Teaching Hospital & Faculty of Medicine, Kuwait University, Jabriya, Kuwait
| | - Issa Loutfi
- Nuclear Medicine Divisions, Mubarak Al Kabeer Teaching Hospital & Faculty of Medicine, Kuwait University, Jabriya, Kuwait
| | - Kamal AS Al-Shoumer
- Endocrinology, Mubarak Al Kabeer Teaching Hospital & Faculty of Medicine, Kuwait University, Jabriya, Kuwait
| |
Collapse
|